2021 AACR: BeiGene Reveals Bazeran® for second/third-line treatment of advanced non-small cells

On April 13, 2021, Beijing time, BeiGene's self-developed anti-PD-1 antibody drug Bezean® (tislelizumab) compared with docetaxel for the second disease progression after platinum-based chemotherapy /Detailed data of the global phase III clinical trial (RATIONALE 303 study) in patients with third-line locally advanced or metastatic non-small cell lung cancer was disclosed at the 112th American Cancer Society Annual Meeting (AACR).

Previously, BeiGene announced that the study had reached the primary endpoint of overall survival (OS) in the interim analysis, and in January this year, it submitted a new report to the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).

Lung cancer is currently the number one malignant tumor in my country in terms of morbidity and mortality.

Immunotherapy is a new direction in the treatment of lung cancer in recent years.

The RATIONALE 303 study, which released the data this time, is a randomized, open, multi-center, global phase III clinical trial conducted by BeiGene, which aims to evaluate Beizian® (tislelizumab) versus docetal The efficacy and safety of Cyx for the treatment of second/third-line locally advanced or metastatic non-small cell lung cancer patients who have undergone disease progression after receiving platinum-based chemotherapy.

From the data released this time, compared with traditional chemotherapy, Bezian® (tislelizumab) has shown more significant clinical benefits, specifically in:

1.

2.

3.

4.

5.